dc.contributor.author | Weller, A | |
dc.contributor.author | Papoutsaki, MV | |
dc.contributor.author | Waterton, JC | |
dc.contributor.author | Chiti, A | |
dc.contributor.author | Stroobants, S | |
dc.contributor.author | Kuijer, J | |
dc.contributor.author | Blackledge, M | |
dc.contributor.author | Morgan, V | |
dc.contributor.author | deSouza, NM | |
dc.date.accessioned | 2017-08-03T13:59:26Z | |
dc.date.issued | 2017-11-01 | |
dc.identifier.citation | European radiology, 2017, 27 (11), pp. 4552 - 4562 | |
dc.identifier.issn | 0938-7994 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/759 | |
dc.identifier.eissn | 1432-1084 | |
dc.identifier.doi | 10.1007/s00330-017-4828-6 | |
dc.description.abstract | PURPOSE: To determine the test-retest repeatability of Apparent Diffusion Coefficient (ADC) measurements across institutions and MRI vendors, plus investigate the effect of post-processing methodology on measurement precision. METHODS: Thirty malignant lung lesions >2 cm in size (23 patients) were scanned on two occasions, using echo-planar-Diffusion-Weighted (DW)-MRI to derive whole-tumour ADC (b = 100, 500 and 800smm-2). Scanning was performed at 4 institutions (3 MRI vendors). Whole-tumour volumes-of-interest were copied from first visit onto second visit images and from one post-processing platform to an open-source platform, to assess ADC repeatability and cross-platform reproducibility. RESULTS: Whole-tumour ADC values ranged from 0.66-1.94x10-3mm2s-1 (mean = 1.14). Within-patient coefficient-of-variation (wCV) was 7.1% (95% CI 5.7-9.6%), limits-of-agreement (LoA) -18.0 to 21.9%. Lesions >3 cm had improved repeatability: wCV 3.9% (95% CI 2.9-5.9%); and LoA -10.2 to 11.4%. Variability for lesions <3 cm was 2.46 times higher. ADC reproducibility across different post-processing platforms was excellent: Pearson's R2 = 0.99; CoV 2.8% (95% CI 2.3-3.4%); and LoA -7.4 to 8.0%. CONCLUSION: A free-breathing DW-MRI protocol for imaging malignant lung tumours achieved satisfactory within-patient repeatability and was robust to changes in post-processing software, justifying its use in multi-centre trials. For response evaluation in individual patients, a change in ADC >21.9% will reflect treatment-related change. KEY POINTS: • In lung cancer, free-breathing DWI-MRI produces acceptable images with evaluable ADC measurement. • ADC repeatability coefficient-of-variation is 7.1% for lung tumours >2 cm. • ADC repeatability coefficient-of-variation is 3.9% for lung tumours >3 cm. • ADC measurement precision is unaffected by the post-processing software used. • In multicentre trials, 22% increase in ADC indicates positive treatment response. | |
dc.format | Print-Electronic | |
dc.format.extent | 4552 - 4562 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Lung Neoplasms | |
dc.subject | Diagnosis, Differential | |
dc.subject | Diffusion Magnetic Resonance Imaging | |
dc.subject | Neoplasm Staging | |
dc.subject | Tumor Burden | |
dc.subject | Prospective Studies | |
dc.subject | Reproducibility of Results | |
dc.subject | ROC Curve | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.title | Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-03-20 | |
rioxxterms.funder | The Institute of Cancer Research | |
rioxxterms.identifier.project | Unspecified | |
rioxxterms.versionofrecord | 10.1007/s00330-017-4828-6 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European radiology | |
pubs.issue | 11 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 27 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Computational Imaging | |
icr.researchteam | Magnetic Resonance | |
dc.contributor.icrauthor | Weller, Alexander | |
dc.contributor.icrauthor | Blackledge, Matthew | |
dc.contributor.icrauthor | deSouza, Nandita | |